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BioluminescenceCell-penetrating peptides (CPPs) are short cationic/amphipathic peptides that can be used to deliver a variety of
cargos into cells. However, it is still debated which routes CPPs employ to gain access to intracellular compart-
ments. To assess this, most previously conducted studies have relied on information which is gained by using
ﬂuorescently labeled CPPs. More relevant informationwhether the internalized conjugates are biologically avail-
able has been gathered using end-point assays with biological readouts. Uptake kinetic studies have shed even
more light on the matter because the arbitrary choice of end-point might have profound effect how the results
could be interpreted. To elucidate uptake mechanisms of CPPs, here we have used a bioluminescence based
assay tomeasure cytosolic delivery kinetics of luciferin–CPP conjugates in the presence of endocytosis inhibitors.
The results suggest that these conjugates are delivered into cytosol mainly via macropinocytosis; clathrin-
mediated endocytosis and caveolae/lipid raft dependent endocytosis are involved in a smaller extent. Further-
more,wedemonstrate how the involved endocytic routes and internalization kinetic proﬁles can dependon con-
jugate concentration in case of certain peptides, but not in case of others. The employed internalization route,
however, likely dictates the intracellular fate and subsequent trafﬁcking of internalized ligands, therefore em-
phasizing the importance of our novel ﬁndings for delivery vector development.
© 2011 Elsevier B.V. All rights reserved.1. Introduction
Cell-penetrating peptides (CPPs) are relatively short cationic and/
or amphipathic peptides capable of delivering many types of cargos
into mammalian cells. The ﬁrst CPPs, penetratin [1] and Tat [2],
were discovered in 1994 and 1997, respectively, and numerous
other CPPs have been reported ever since. The range of CPP-
compatible cargo molecules is wide and it includes many types of
therapeutic proteins and peptides, nucleic acids, cytotoxic agents
and imaging contrast agents [3]. In order to mediate its corresponding
biological effect, each cargo type needs to reach the speciﬁc intracel-
lular compartment, such as the cytoplasm or the nucleus [4–6]., Short interfering ribonucleic
growth factor receptor; CME,
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l rights reserved.However, it is still actively debated which mechanisms are involved
in CPP-mediated cargo delivery and whether the mechanisms might
differ for reaching separate intracellular targets.
While early reports suggested the involvement of direct (energy
independent) pathways in the internalization process, the conclusion
was based largely on cell ﬁxation artifacts [3]. Thereafter endocytosis
has been considered as the predominant uptake route, especially
when CPPs are carrying cargo molecules. However, some more care-
fully controlled recent studies still suggest that direct translocation
mechanism cannot be overruled in case of some naked or ﬂuorescently
labeled CPPs at certain conditions [7–9].
For both the endocytosis and direct translocation the CPPs interact
with the cell membrane prior to being taken up by cells [8]. The cell
membrane, however, contains many components that are required
for different types of endocytosis [10–14] and different cell lines
might express these constituents in various levels. Composite CPP
properties could therefore lead to multifaceted membrane interac-
tions, and it is thus not surprising why the results of CPP uptake
mechanism studies are not always converging.
It seems that, similarly to uptake of many ligands and receptors
[13], different endocytosis sub-types can be involved simultaneously
in the CPP uptake process [3,15]. Their relative importance and the
subsequent intracellular fate of the internalized material may depend
on numerous factors. For example, at low concentration epidermal
growth factor (EGF) triggers its receptor (EGFR) internalization via
Table 1
Cell-penetrating peptides used in this paper.
CPP Cys-CPP sequence Origin Type Ref.
MAP C-KLALKLALKALKAALKLA-amide Synthetic Secondary
amphipathic
[52]
TP10 C-AGYLLGKINLKALAALAKKIL-
amide
Chimeric Primary
amphipathic
[53]
TP10(Cys) AGYLLGK(C)aINLKALAALAKKIL-
amide
Chimeric Primary
amphipathic
[53]
EB1 C-
LIRLWSHLIHIWFQNRRLKWKKK-
amide
Chimeric Secondary
amphipathic
[54]
Penetratin C-RQIKIWFQNRRMKWKK-amide Protein
derived
Secondary
amphipathic
[1]
pVec C-LLIILRRRIRKQAHAHSK-amide Protein
derived
Secondary
amphipathic
[55]
Tat C-GRKKRRQRRRPPQ-amide Protein
derived
Non-
amphipathic/
cationic
[2]
M918 C-MVTVLFRRLRIRRASGPPRVRV-
amide
Protein
derived
Non-
amphipathic/
cationic
[56]
a Luciferin was coupled to the cysteine at the ε-amino group on Lys7.
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recycled back to the membrane. However when the EGF concentra-
tion is increased the uptake of EGFR is routed to a non-CME pathway
during which the receptor will be degraded [13]. Since many CPPs are
derived from proteins it could be hypothesized that similar processes
to the previously described example could also occur when delivering
cargos with CPPs, thus making it important to study their internaliza-
tion pathways [13,16].
Most studies in the ﬁeld regarding CPP uptake mechanisms are
end-point studies. While biological readout systems are exploited in
some investigations (e.g. the delivery of enzymes or oligonucleo-
tides), mostly ﬂuorophore-labeled peptides have been used. Further-
more, CPP uptake kinetic measurements should be preferred to end-
point studies because in an arbitrarily chosen end-point certain ef-
fects of endocytosis inhibitors and thus the involvement of certain
pathways could be left unregistered. Further, differences between
peptides that might display similar overall internalization degree
may have completely different kinetic proﬁles which could not be no-
ticed using end-point assays [17].
In this paper we have used luciferin-conjugated CPPs (luciferin–
CPPs) to evaluate CPP uptake mechanisms. Previously we have used
a semi-biological real-time uptake kinetics assay [18,19] to character-
ize CPPs based on their uptake kinetics proﬁles [17]. In the latter
study we showed that CPPs can be divided into two distinct groups
—the fast internalization group (TP10, MAP and Tat) whose uptake ki-
netics proﬁle resembled the behavior of membrane permeable free
luciferin, and the slow uptake group (TP10(Cys), pVec, M918, pene-
tratin and EB1) whose uptake proﬁle was more consistent with the
uptake rates conventionally observed in case of endocytosis.
Here we used the same assay to assess the effects of selected en-
docytosis inhibitors on the CPP cytosolic uptake kinetics proﬁles of
the both CPP groups. We will show that endocytosis is extensively in-
volved in the cytosolic delivery of all the tested luciferin–CPP conju-
gates, even in case of the fast uptake group peptides despite their
behavior resembles the membrane permeable free luciferin. We will
also discuss how different luciferin–CPP conjugates can utilize pre-
ferred endocytosis sub-type depending on the conjugate
concentration.
2. Materials and methods
2.1. Peptide synthesis
The peptides used in this study (Table 1) were synthesized using a
solid phase peptide synthesis (SPPS) method on an automated pep-
tide synthesizer (ABI 433A, Applied Biosystems, USA). In the synthe-
sis tert-butyloxycarbonyl (t-Boc) chemistry was used. Shortly, t-Boc
amino acids (Neosystem, France; Iris Biotech, Germany; Bachem AG,
Switzerland) were coupled as hydroxyl-benzotriazole (HOBt) esters
(Iris Biotech, Germany) in the presence of N,N′-dicyclohexylcarbodii-
mide (DCC; Iris Biotech, Germany) and N,N′-diisopropylethylamine
(DIEA; Iris Biotech, Germany) to a 4-methylbenzhydryl-amine resin
(Iris Biotech, Germany). This yielded in C-terminally amidated
peptides.
TP10 peptide was modiﬁed by manual coupling of the Cys residue
to the ε-amino group on its Lys7 to obtain TP10(Cys) peptide. The Cys
residue was activated by HOBt, 2-(1H-benzotriazole-1-yl)-1,1,3,3-
tetramethyl-aminium tetraﬂuoroborate (TBTU) and DIEA.
Before being cleaved from the resin, peptides containing
His(Dnp) or Trp(For) were deprotected with 20% thiophenol in N,N′-
dimethylformamide (DMF) for 1 h or 20% piperidine in DMF for
1 h, respectively. All peptides were cleaved from the resin using an-
hydrous hydrogen ﬂuoride/p-cresol/p-thiocresol (90/5/5) solution
for 1 h at 4 °C. After cleavage the peptides were ether-precipitated
and ﬁnally puriﬁed by semi-preparative reverse-phase HPLC column
(Discovery®BIO Wide Pore C-18, Supelco®, Sigma-Aldrich, Sweden).Their purity was determined by RP-HPLC analytical column (Discovery®
C-18, Supelco®) and correct molecular weight was veriﬁed by MALDI-
TOF (Perkin Elmer prOTOF™ 2000, Perkin Elmer, Sweden) mass
spectrometry.
2.2. Synthesis of luciferin–CPP conjugates
Luciferin-linker was synthesized as previously reported (see
Scheme 1 in [20]). Luciferin-linker and Cys-CPPs were mixed in 1:1
molar ratio at 0.88 mM concentration in DMF/acetic acid buffer (pH
5, 50 mM) for 1 h under nitrogen. Luciferin–CPP conjugates were pu-
riﬁed by semi-preparative RP-HPLC column, and their purity (>99%)
was analyzed by RP-HPLC analytical column. The correct molecular
weight was veriﬁed by MALDI-TOF mass spectrometry.
2.3. Cell culture
HeLa pLuc 705 cells, kindly provided by Ryszard Kole [21], were
grown in DMEM (Dulbecco's modiﬁed Eagle's medium) with gluta-
max and supplemented with 0.1 mM non-essential amino acids,
1.0 mM sodium pyruvate, 10% fetal bovine serum (FBS), 100 U/ml
penicillin, and 100 mg/ml streptomycin (hereafter referred to as com-
plete medium). For uptake kinetics experiments, complete medium
without phenol red was used. Cells were grown in a humidiﬁed 5%
CO2 environment at 37 °C. Cell culture media and supplements were
purchased from Invitrogen, Sweden.
2.4. Uptake kinetics
2×105 cells were seeded onto a 6-well cell culture plate (day 1).
24 h later (on day 2) 4 μg luciferase encoding pGL3 plasmid (Pro-
mega, Sweden) was complexed with 10 μl Lipofectamine™ 2000 re-
agent (Invitrogen, Sweden) and the cells were transfected with the
plasmid according to the manufacturer's instructions in 2.5 ml com-
plete medium for 4 h. After that the transfection medium was
replaced with fresh complete medium and the cells grown for further
20 h. After that, on day 3, 9×103 cells were seeded in a white 96-well
clear-bottom plate (Greiner Bio-One, Germany) and 24 h after seed-
ing, on day 4, the cells were treated with luciferin–CPP conjugates.
On the day of the experiment the cells were washed once with
100 μl complete cell culture media, after which 30 min pre-
incubation with endocytosis inhibitors was conducted. The inhibitors
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treatment was carried out in a humidiﬁed 5% CO2 environment at
37 °C.
For endocytosis inhibitors we used 10 μM chlorpromazine (Cpz)
to inhibit clathrin mediated endocytosis (CME), 4 μM cytochalasin
D (CyD) to inhibit macropinoctytosis (MP), and 50 μM nystatin
(Nys) to inhibit caveolae/lipid raft dependent endocytosis (C/LR)
(Table 2).
These inhibitors were chosen to have minimized cross-inhibition
effects [22]. In addition 100 μM chloroquine (CQ) was used. CQ is con-
ventionally used in biological assays to inhibit acidiﬁcation rate of
early endosomes and to promote release of the endosomally
entrapped material in long term; however as a side effect of deceler-
ated acidiﬁcation, vesicle recycling is slowed too which could slow
down overall endocytosis rate [23,24]. By using CQ we aimed to test
which of these mechanisms prevail in early uptake kinetics.
After pre-treating the cells with endocytosis inhibitors, the incu-
bation media was replaced with various concentrations of 120 μl lu-
ciferin–CPP solution in complete medium without phenol red. The
endocytosis inhibitors were present during luciferin–CPP treatment.
All experiments were carried out at RT (25 °C) for 2 h (in complete
medium) in atmospheric CO2. Luminescence was measured by GLO-
MAX™ 96 microplate luminometer (Promega, Sweden) where data
points were recorded in 1.5 min time interval.
To analyze how the used endocytosis inhibitors Nys, Cpz, CyD and
CQ affect the overall luciferin–CPP uptake at different incubation time
points, we calculated the area-under-curve (AUC, in RLU units) of the
registered kinetics curves (measured in units RLU/s) after 15, 30, 60
and 120 min incubation with luciferin–CPP conjugates in the pres-
ence of these endocytosis inhibitors. We normalized the calculated
AUC values to AUC of the control (no inhibitor treated) sample at
the same time points. For example, the value 0.80 marks that the in-
hibitor decreases the overall uptake by 20% compared to the control,
whereas 1.20 states that under current conditions the overall uptake
was increased by 20% compared to the control.2.5. Lactate dehydrogenase (LDH) leakage
To assess possible membranolytic effects and short term toxicity
of luciferin–CPP conjugates, LDH leakage from cells was measured
using the Promega CytoTox-ONE™ assay (Promega, USA). Cells were
seeded and treated similarly to the uptake kinetics experiments and
the CytoTox-ONE™ assay was carried out according to the manufac-
turer's protocol. LDH release from cells lysed with 0.2% Triton X-100
in HKRg was deﬁned as 100% leakage, and LDH release from
untreated cells as 0% leakage.Table 2
Endocytosis inhibitors used in this paper.
Inhibitor Mechanism Affected
pathway
CME* MP* C/LR*
Chlorpromazine Clathrin/AP2 depletion from plasma
membrane to endosomal membranes
++
+
+ –
Cytochalasin D Blocking of actin polymerization,
disassembly of actin cytoskeleton
+ ++
+
+
Nystatin Binding to plasma membrane
cholesterol
− − ++
+
Chloroquine Slows down acidiﬁcation of endosomal
vesicles, promotes endosomal escape
+ + +
*CME—clathrin mediated endocytosis; MP—macropinocytosis; C/LR—caveolae/lipid
raft dependent endocytosis.2.6. Statistical analysis
All data were processed in GraphPad Prism version 5 for Windows
(GraphPad Software Inc., USA) with results displayed as mean±SEM.
The uptake kinetics measurements consist of three independent
experiments performed in triplicate. The cytotoxicity measure-
ments include two independent experiments performed in
triplicate.
3. Results
In this paper we measured the cytosolic cargo delivery kinetics of
eight CPPs Tat, MAP, TP10, TP10(Cys), pVec, M918, penetratin and
EB1 (Table 1) using a bioluminescence assay [18]. Shortly, in this
assay luciferin is conjugated to a speciﬁc thiolated linker [20] that in
turn is attached to a cysteine-containing CPP via a disulﬁde bond.
When these conjugates reach cytoplasm the disulﬁde bridge is re-
duced by glutathione, the linker self-cyclicizes and is thus removed
from the luciferin molecule. During this process free luciferin is re-
leased which is the substrate for luciferase enzyme. The enzyme con-
verts luciferin into oxyluciferin and a photon of light is produced
(Fig. 1). The rate of this reaction reﬂects the uptake rate of the lucifer-
in–CPP conjugates at a given time point. By registering it over time,
real time uptake kinetics curve can be obtained (Fig. 2).
3.1. Effects of endocytosis inhibitors on the total luciferin–CPP uptake at
various incubation times
First we analyzed how the used endocytosis inhibitors nystatin
(Nys), chlorpromazine (Cpz), cytochalasin D (CyD) or chloroquine
(CQ) (Table 2) affect the overall luciferin–CPP uptake at different incu-
bation time points—15, 30, 60 and 120 min (Table 3, Supplementary
Fig. 1).
It seems that the overall uptake of all the peptide conjugates, ex-
cept luciferin-Tat, is affected most by CyD treatment. Generally this
inhibitor has stronger effects at longer incubation times (Table 3, Sup-
plementary Fig. 1). Nys tends to inhibit the overall internalization of
the conjugates when their concentration is high, except for Tat,
M918 and penetratin in case of which almost no statistically signiﬁ-
cant inhibition is observed. Rather interestingly, Nys seems to in-
crease the internalization of lower concentrations of Tat, MAP, pVec
and EB1 conjugates (Table 3, Supplementary Fig. 1). In some cases
also Cpz co-incubation leads to increased uptake, e.g. in case of Tat
and MAP conjugates. In case of other peptides Cpz treatment tends
to inhibit the overall uptake (Table 3, Supplementary Fig. 1).
CQ, a generally used endosomolytic agent, is able to increase the
overall uptake of only Tat, MAP and TP10 conjugates, and not at
every concentration (Table 3, Supplementary Fig. 1). However, in
case of TP10(Cys), CQ treatment leads to an interesting change of its
uptake kinetics proﬁle. In the presence of CQ the uptake rate kinetics
curve seems to be bi-phasic as the kinetics proﬁle displays an addi-
tional linear increase after having previously reached a temporary
plateau value (Fig. 2). This can be observed also in case of lower con-
centrations of MAP, TP10 and M918 conjugates and at higher concen-
trations of pVec and penetratin (Fig. 2).
The endocytosis inhibitors do not inhibit the cytosolic delivery of
the positive control free luciferin (Fig. 3).
Endocytosis inhibitors can have profound effects on CPP uptake ki-
netic proﬁles, as mentioned above. The inhibitor treatment changes
the time at which the maximal uptake rate is observed, but clear cor-
relations among peptides, even within the fast and slow uptake group
peptides, are difﬁcult to deﬁne (Supplementary Table 1). Similarly,
the relative maximal uptake rate of luciferin–CPP conjucates depends
on the inhibitor treatment as well. While in case of the fast uptake
group CPPs the inhibitors tend to affect this parameter less than in
++
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Fig. 1. Intracellular fate of the luciferin–CPP conjugates. The luciferin–CPP conjugates (A) enter cells. In the reducing environment of cytoplasm, the CPP is cleaved from the conjugate by
glutathione (B) and the linker goes through spontaneous cyclization and is cleaved from the luciferin molecule and free luciferin is released (C). Free luciferin is a substrate for luciferase
enzyme which converts it to oxyluciferin, releasing a photon of light in the process (D).
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not emerge (Supplementary Table 2).
3.2. Peptide toxicity by lactate dehydrogenase (LDH) leakage assay
Next we estimated whether the peptides together with the used
endocytosis inhibitors affect cell membrane integrity because the lu-
ciferin–CPP conjugates might leak into the cells through damaged
membranes. At the same time the otherwise cytoplasm-restricted
glutathione might potentially leak out of the cells and cleave the
CPP from luciferin molecule prematurely. Both of the processes
could result in the overestimation of cytosolic delivery capacity of
toxic CPPs. We assessed the possible toxic effects by measuring the
leakage of intracellular LDH to the extracellular environment in two
representative time points, at 30 and 120 min (Fig. 4).
The slow uptake group peptides (TP10(Cys), pVec, M918, penetra-
tin and EB1) can generally be considered non-toxic throughout the
experiment even if co-incubated with the used endocytosis inhibi-
tors; miniscule toxicity is observed only in case of TP10(Cys). In
case of the latter CPP conjugate the relative LDH leakage remained
well below 5% in most cases, however CQ, CyD and Cpz co-
treatment leads to approximately 10% LDH leakage at 10 μM conju-
gate concentration. The toxicity was in the similar level also when
high concentration of the EB1 conjugate was incubated together
with Nys or CQ. For details, see Fig. 4.
Toxicity proﬁle of the fast internalizing group conjugates (Tat,
MAP and TP10) is divergent. 10 μM MAP and TP10 display consider-
ably high LDH leakage at 120 min incubation while it is much less
pronounced in 30 min time point and insigniﬁcant at lower conjugate
concentrations (Fig. 4). This suggests that the toxic effects in the early
incubation times are not the cause of the observed uptake. The toxic-
ity of these two latter peptides is increased even further by certain
endocytosis inhibitors. When co-incubated with CQ, the LDH leakage
is increased at 10 μM conjugate concentration during 30 min incuba-
tion; and it becomes signiﬁcant in case of 5 μM concentration at the
120 min incubation time point. Cpz, and to some extent also Nys, pos-
sesses similar effects on the TP10 conjugate but interestingly not on
MAP. As opposed to the other fast group CPPs Tat does not mediate
any cellular toxicity at any tested concentration according to the
LDH leakage assay. Co-incubation of the Tat conjugate with endocyto-
sis inhibitors does not affect its toxicity either.
4. Discussion
There are still controversies regarding which pathways exactly are
involved in CPP uptake. It seems that the consensus view is thatendocytic routes and vesicular uptake are almost exclusively used at
least when CPPs are attached to larger cargos. However, direct cell
membrane translocation/non-vesicular transport cannot be ruled
out either because CPPs are shown to interact strongly with biological
membranes. Some groups have postulated that the latter is activated
above a certain CPP concentration threshold [9] whereas according to
other models direct penetration is active rather at low concentrations
(below 2 μM) [25–27], which adds further controversies.
The extent in which different active transport/endocytosis related
internalization routes are involved in the uptake process is actively
debated to address the existing controversies. The employed endocy-
tosis route might depend on several factors, including which
membrane-bound molecule a certain CPP interacts with. Different
CPP types may have distinct cell membrane interaction partners,
such as charged/uncharged membrane phospholipids, negatively
charged GAGs, syndecans and glypicans, that might take part in vari-
ous endocytic processes [8,10,11]. Therefore, the comparison of CPP
uptake mechanisms studies is often complicated because the mem-
brane composition can differ largely among cell types. This all empha-
sizes the need for more systematic studies on the latter topic.
It has been hypothesized that different endocytosis routes are si-
multaneously involved in CPP uptake and that these parallel mecha-
nisms can compensate each other [3,15]. This may lead to data
misinterpretation when the overall uptake only in a single time
point is measured. We have previously shown that, in certain cases,
the inhibitors tend to affect only the uptake rate while the overall
total uptake remains unchanged when incubation is carried out long
enough, while in other cases the trend is reversed [28]. Further,
there can be profound discrepancies among CPPs regarding their up-
take kinetics proﬁles [17] and the effects of endocytosis inhibitors on
these proﬁles are left unregistered in single time point experiments.
Thus kinetic studies could be more informative when studying CPP
uptake mechanisms but nevertheless generally the CPP kinetics has
not been quantiﬁed. Few attempts, however, have been made to ad-
dress the issue. For example measurement of 125I-biotinyl-transportan
kinetics in Bowes' melanoma cells [29], NBD penetratin kinetics in
K562 cells [30,31], [99mTc]Tat [32] and ﬂuoresceinyl-Tat kinetics in Jur-
kat cells [33] have been reported. Internalization kinetics of rhodamine-
labeled Tat, polyarginine [34,35], transportan and penetratin [35] have
been estimated as well. More recently, the uptake kinetics of modiﬁed
ﬂuorescein-labeled polyarginine [36], ﬂuorescein-labeled programmed
cell death inducing cyclic hexapeptide conjugated to an arginine rich
CPP [37], and ﬂuorescein or TAMRA labeled L- or D-isomer of polyargi-
nine [38] has been reported and we have measured cytosolic delivery
kinetics of CPPs using a quenched ﬂuorescence assay [28] and a biolu-
minescence based assay [17]. These kinetic studies have demonstrated
Peptide
Concentration
2.5 µM 5 µM 10 µM
Ta
t
0 30 60 90 120
0.000
0.005
0.010
0.015
0.020
Time (min)
RL
U/
s
0 30 60 90 1200.000
0.005
0.010
0.015
0.020
Time (min)
R
LU
/s
0 30 60 90 120
0.000
0.005
0.010
0.015
0.020
Time (min)
R
LU
/s
0 30 60 90 120
0.000
0.005
0.010
0.015
0.020
0.025
Time (min)
R
LU
/s
0 30 60 90 120
0.00
0.01
0.02
0.03
Time (min)
RL
U/
s
0 30 60 90 120
0.00
0.02
0.04
0.06
0.08
Time (min)
RL
U/
s
0 30 60 90 120
0.000
0.005
0.010
0.015
0.020
Time (min)
R
LU
/s
0 30 60 90 120
0.000
0.005
0.010
0.015
Time (min)
R
LU
/s
0 30 60 90 120
0.00
0.01
0.02
0.03
0.04
0.05
Time (min)
RL
U/
s
0 30 60 90 120
0.000
0.005
0.010
0.015
Time (min)
R
LU
/s
0 30 60 90 120
0.000
0.005
0.010
0.015
Time (min)
R
LU
/s
0 30 60 90 120
0.000
0.005
0.010
0.015
Time (min)
R
LU
/s
0 30 60 90 120
0.000
0.005
0.010
0.015
Time (min)
R
LU
/s
0 30 60 90 120
0.000
0.005
0.010
0.015
Time (min)
R
LU
/s
0 30 60 90 120
0.000
0.005
0.010
0.015
Time (min)
R
LU
/s
0 30 60 90 120
0.000
0.005
0.010
0.015
Time (min)
R
LU
/s
0 30 60 90 120
0.000
0.005
0.010
0.015
Time (min)
R
LU
/s
0 30 60 90 120
0.000
0.005
0.010
0.015
Time (min)
R
LU
/s
0 30 60 90 120
0.000
0.005
0.010
0.015
0.020
0.025
Time (min)
R
LU
/s
0 30 60 90 120
0.000
0.005
0.010
0.015
Time (min)
R
LU
/s
0 30 60 90 120
0.000
0.005
0.010
0.015
Time (min)
R
LU
/s
0 30 60 90 120
0.000
0.005
0.010
0.015
0.020
Time (min)
R
LU
/s
0 30 60 90 120
0.000
0.005
0.010
0.015
Time (min)
R
LU
/s
0 30 60 90 120
0.000
0.005
0.010
0.015
Time (min)
R
LU
/s
M
A
P
TP
10
TP
10
(C
ys
)
pV
ec
M
91
8
Pe
ne
tra
tin
EB
1
Nys
Cpz
CyD
CQ
No inhib
Fig. 2. CPP cytosolic cargo delivery rate kinetic proﬁles in thepresence of endocytosis inhibitors. HeLa pLuc 705 cellswere incubatedwith various concentrations of Luc–CPP conjugates in the
presence of endocytosis inhibitors nystatin (Nys), chlorpromazine (Cpz), cytochalasin D (CyD), or chlorquine (CQ). In the control sample no inhibitors were used (No inhib). Theﬁgures rep-
resent average of three independent experiments, each performed in triplicate, the error bars represent standard error of mean (SEM).
506 I. Mäger et al. / Biochimica et Biophysica Acta 1818 (2012) 502–511
Table 3
Relative inhibition of the overall uptake of Luc-CPP conjugates. Theﬁgures represent relative overall uptake compared to the control (no inhibitor) sample±SEM. Values>1 indicate that the
overall luciferin–CPP uptake in the presence of inhibitors increased. The conditionswhere the inhibitionwas statistically not signiﬁcant, according to the two-way ANOVA using Bonferroni's
post-hoc test, are denoted with “–.”
CPP Inc.
Time
Nystatin Chlorpromazine Cytochalasin D Chloroquine
2.5 μM 5 μM 10 μM 2.5 μM 5 μM 10 μM 2.5 μM 5 μM 10 μM 2.5 μM 5 μM 10 μM
Tat 15 min 1.34
±0.05
1.20
±0.09
– – – – – – – – – –
30 min 1.34
±0.06
– – – – – – – – – – –
60 min 1.34
±0.08
– – 1.43
±0.13
– – – – – – – –
120 min 1.33
±0.08
– – 1.46
±0.12
1.17
±0.05
– – – – 1.33
±0.09
1.24
±0.07
–
MAP 15 min .46±0.13 – 0.79
±0.05
1.47
±0.12
– – – 0.51
±0.07
0.71
±0.03
1.42
±0.10
– 1.48
±0.10
30 min – – 0.86
±0.04
1.71
±0.16
– 1.52
±0.16
– 0.52
±0.07
– 1.44
±0.11
– 1.48
±0.09
60 min – – – 1.83
±0.17
– 1.51
±0.13
0.62
±0.03
0.58
±0.07
– 1.42
±0.12
– 1.41
±0.08
120 min – – – – – 1.46
±0.10
0.49
±0.03
0.57
±0.07
– – – 1.39
±0.08
TP10 15 min – – 0.76
±0.07
– – 0.79
±0.11
– – 0.78
±0.09
– 1.39
±0.02
1.22
±0.08
30 min – – 0.75
±0.04
– – – 0.73
±0.08
0.80
±0.05
– – – –
60 min – – 0.75
±0.03
– – – 0.61
±0.07
0.71
±0.04
– – – –
120 min – 0.16
±0.04
0.77
±0.02
– – – 0.54
±0.07
0.67
±0.04
– 1.34
±0.08
– –
TP10(Cys) 15 min – – 0.68
±0.06
– – – – – 0.65
±0.08
– – –
30 min – – 0.62
±0.04
– – – 0.62
±0.02
– 0.44
±0.06
– – –
60 min – – – – – – 0.45
±0.01
0.60
±0.07
– – – –
120 min – – – 0.69
±0.05
0.67
±0.08
0.75
±0.04
0.32
±0.01
0.41
±0.04
– – – –
pVec 15 min – 1.29
±0.12
– – – – – – – – – –
30 min – – 0.78
±0.06
– – – – – 0.65
±0.02
– – 0.75
±0.02
60 min 1.35
±0.08
– 0.72
±0.03
– – 0.66
±0.03
– 0.63
±0.04
0.48
±0.02
– – 0.74
±0.02
120 min 1.43
±0.08
– 0.70
±0.01
– 0.71
±0.06
0.53
±0.02
0.59
±0.03
0.45
±0.02
0.34
±0.01
– – 0.73
±0.02
M918 15 min – – – – – – – – – – – –
30 min – – – – – – 0.66
±0.06
– – – – –
60 min – – – – 0.71
±0.07
– 0.43
±0.04
0.53
±0.04
0.61
±0.03
0.68
±0.03
0.67
±0.04
–
120 min – – – 0.66
±0.07
0.58
±0.05
0.64
±0.04
0.30
±0.02
0.41
±0.03
0.47
±0.02
0.66
±0.02
0.65
±0.03
–
Penetratin 15 min – – – – – – – – – – – –
30 min – – – – – – 0.76
±0.05
0.71
±0.03
– – – –
60 min – – – – – – 0.60
±0.04
0.58
±0.02
– – – –
120 min – – – 0.82
±0.03
– – 0.51
±0.04
0.50
±0.02
0.69
±0.05
– – –
EB1 15 min 1.19
±0.06
– – – – – – – – – – –
30 min – 0.22
±0.07
– – 0.86
±0.03
– 0.63
±0.02
0.66
±0.03
0.73
±0.06
– – –
60 min – 0.33
±0.06
– – 0.78
±0.02
– 0.43
±0.02
0.42
±0.02
0.48
±0.04
– 0.80
±0.09
–
120 min – 0.33
±0.05
– 0.74
±0.05
0.66
±0.02
– 0.31
±0.01
0.31
±0.01
0.36
±0.03
– 0.72
±0.07
–
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[17], with uptake half-times as low as 2–12 min [32,34,39]. In most
cases, however, the uptake is slower, with internalization half-life
reaching 60 min [17,28,31,39]. The mentioned studies are informative
but they generally tend to have one important drawback. Namely the
registered signal often arises from the material still entrapped inendosomes. When CPP mechanisms are studied in these settings then
the biologically available material cannot be correctly assessed.
There have been attempts to overcome this problem by designing
quenched ﬂuorescence based probes, i.e. by attaching a ﬂuorophore
to a CPP and a corresponding quencher to its cargo, or vice versa,
and conjugating the two molecules to each other over a disulﬁde
0 30 60 90 120
0.000
0.001
0.002
0.003
Nystatin
Chlorpromazine
Cytochalasin D
Chloroquine
No inhibitor
Time (min)
R
LU
/s
Fig. 3. Example of the uptake kinetics curve of the positive control (membrane permeable
free luciferin). The uptake is fast and the used endocytosis inhibitors do not lower the uptake
rate. HeLa pLuc 705 cells were incubatedwith 10 μMfree luciferin and the luminescencewas
measured over time.
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sulﬁde bridge is cleaved and quenching is lost, after which the conju-
gates start to ﬂuoresce.
Disulﬁde bonds that are used in the mentioned methods are con-
ventionally believed to be cleaved by intracellular concentration of
glutathione which represents the major component of cellular redox
system [41]. Nevertheless, there are enzymes responsible for con-
trolled disulﬁde cleavage reactions as well, such as protein disulﬁde
isomerase (PDI) and other Trx family enzymes. This might raise a
question whether these proteins could facilitate disulﬁde bridge
cleavage on a cell membrane. However this does not seem to be a
case as we have not observed any increase of extracellular free thiols
when incubating luciferin–CPPs with cells [17], similarly to the origi-
nal works conducted with this assay [18]. Indeed, PDI system requires
an efﬁcient thiol regenerating system, such as glutathione, but this is
not found on the outer surface of cell membranes [41]; additionally
PDI seems to be excluded from the membranes of macropinosomes
[42]. For example, in a thorough study regarding the delivery of
antibody-drug conjugates it was demonstrated that the overall condi-
tions in endocytic pathways are oxidizing and the reductive disulﬁde
bond cleavage is very inefﬁcient [43].
There seems to be a disulﬁde processing activity, however, in
endosomes of some speciﬁc cell types, e.g. antigen presenting cells re-
quire gamma-interferon-inducible lysosomal thiol reductase (GILT)Fig. 4. CPP and inhibitor induced LDH leakage compared to the untreated samples. HeLa pLu
presence/absence of endocytosis inhibitors and LDH leakage was measured using the CytoT
leakage from lysed cells as 100% leakage. The data represent two independent experimentsfor correct presentation of the endocytosed antigens [41]. GILT is ac-
tive at low pH and is regenerated by free cysteine instead of glutathi-
one. Despite having an intrinsic function in antigen presenting cells,
GILT-like endosomal thiol processing events might occur also in
other cell types, as indicated by the cleavage of disulﬁde bond based
FRET probes [44]. This cleavage occurs, however, with a half-life of
6 h which notably longer time than the course of our CPP uptake ki-
netics experiments. Furthermore, the half-life of luciferin–CPP conju-
gates was shown to be 11 h [18] which signiﬁcantly lowers the
possibility that the CPP conjugates could be actively degraded in the
endolysosomal pathway and that the degradation products could dif-
fuse through vesicle membranes, leading to false-positive readouts.
Thus we hypothesize that the main signal in the used kinetic assay
arises from the conjugates reaching cytoplasm. Indeed, the CPP half-
lives in this investigation seem to be much longer compared to stud-
ies in which the internalization kinetics reﬂect also the endosomally
accumulating peptide conjugates [17,32,34,39].
The quenched ﬂuorescence based strategies are useful for asses-
sing the CPP cytosolic uptake mechanisms but they are not free
from limitations. For example, measurements are often restricted to
suspension cells or complicated experimental setup is required for
growing cells on thin ﬁlms instead of tissue culture plates
[28,39,40]. Also, because the ﬂuorescence is never fully quenched it
might be difﬁcult in some cases to distinguish the high amount of
endosomally entrapped conjugates that have not yet reached the cy-
toplasm from the low amount of cytosolic peptide when in the latter
case the endosome-conﬁned conjugate amount is small.
We are using luciferin-conjugated CPPs [18] to assess their cyto-
solic cargo delivery kinetics and mechanisms. Similarly to the
quenched ﬂuorescence assays, luciferin is released when the conju-
gates reach the cytoplasm (Fig. 1). In cytoplasm the expressed lucifer-
ase enzyme converts luciferin into oxyluciferin which is accompanied
by the emission of luminescence. The issues arising from incomplete
quenching are eliminated because neither the endosomally
entrapped conjugates nor uncleaved luciferin molecules cannot be
substrates for the enzyme. The luciferin assay allows to distinguish
clearly different uptake kinetic proﬁles [17] and to describe the cyto-
plasmic cargo delivery kinetics in the presence of endocytosis inhibi-
tors. Based on our hypothesis the rate limiting factor, and thus the
origin of readout in this assay, is entry of luciferin–CPP conjugates
into cytoplasm. Indeed, in case of fast-internalizing peptides the lumi-
nescence signal starts to increase without a lag period.c 705 cells were treated with various concentrations of luciferin–CPP conjugates in the
ox-One™ assay. The LDH leakage from untreated cells was regarded as 0% leakage and
, performed in triplicate, and the error bars describe standard error of mean (SEM).
Table 4
Concentration dependent involvement of endocytosis pathways in luciferin–CPP
uptake.
Endocytosis
pathway
Involvement of the pathway is the most pronounced…
… at low
conjugate
concentration
… at high
conjugate
concentration
… at every conjugate
concentration of no
correlation
Clathrin mediated
endocytosis
Penetratin,
EB1
M918, pVec Tat,MAP, TP10, TP10
(Cys)
Macropinocytosis Tat, MAP,
TP10
– TP10(Cys), pVec,
M918, penetratin, EB1
Caveolae/lipid raft
dependent endocytosis
– Penetratin,
EB1, M918,
pVec
Tat, MAP, TP10, TP10
(Cys)
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luciferase reaction, are not expected to be rate limiting. Of course, the
disulﬁde cleavage reduction reaction is by far not trivial because in ad-
dition to glutathione different enzymes, such as PDI, participate in the
process aswell and the reaction involves potentially up to nine different
steps [45]. However, it seems that when PDI catalyzes the glutathione-
mediated cleavage then the disulﬁde reduction is expected to occur
within minutes [45]. Upon disulﬁde cleavage, the linker self-
cyclization is very fast, it is completed probably within seconds [18],
and luciferin–luciferase reaction reaches its maximum rate in less
than a second [46].
Based on the prior mentioned hypothesis, in the current study we
used this kinetic assay to evaluate CPP uptake mechanisms. First we
analyzed how the used endocytosis inhibitors Nys, Cpz, CyD and CQ
(Table 2) affect the overall cytosolic delivery of the luciferin–CPP con-
jugates in different time points (Fig. 2, Table 3, Supplementary Fig. 1).
According to this, CyD (an inhibitor of macropinocytosis) seems to be
the most efﬁcient inhibitor for all the tested peptides except Tat.
Stronger inhibition is generally observed at longer incubation times.
Macropinocytosis has been previously shown to be involved in CPP
uptake especially in case of cargo-conjugated cationic peptides
[3,15]. Our results are partly in line with a CPP mechanisms study
based on a biological readout where the nuclear delivery of M918,
penetratin and Tat was found to be strongly dependent on macropi-
nocytosis [47]. This is not surprising because it has been suggested
that macropinosomes might bypass the degrading lysosomal pathway
[48] thus potentially enabling more efﬁcient release of luciferin–CPP
conjugates into the cytoplasm. However cytoplasmic entry of
luciferin-TP10 conjugate was rather insensitive to the treatment with
a CME inhibitor Cpz, contrasting to the previously mentioned study
according to which the nuclear delivery of helical peptides depends
strongly on CME [47]. The latter, however, does not seem to be a ten-
dency in cytoplasmic entry, however cargo type dependent effects can-
not be excluded.
In addition to macropinocytosis other pathways are also involved.
For example, CME seems to be extensively used in the internalization
of all the slow uptake group peptides, although in a considerably lesser
extent (Fig. 2). While in case of TP10(Cys) the involvement of CME ap-
pears similar at every tested conjugate concentration, then in case of
M918 and pVec the CME is more involved at higher conjugate concen-
trations and in case of penetratin and EB1 the trend is reversed, accord-
ing to our data. Nys co-treatment reveals that lipid raft/caveolae
dependent endocytosis is involved at high luciferin–CPP concentra-
tions, perhaps indicating the presence of compensatory transport
mechanisms.
Interestingly, even the uptake of the fast internalizing CPP conju-
gates is affected by the endocytosis inhibitors (Fig. 2, Table 3), demon-
strating a strong involvement of active transport in their uptake
despite these curves closely resemble the behavior of membrane per-
meable naked luciferin as observed previously [17]. However this is
not surprising because endocytosis can be very fast when participating
for example in intrinsic receptor internalization tasks.
These results collectively indicate that the relative incorporation
of different uptake routes may change depending on the peptide con-
centration and that more than one route could indeed be activated si-
multaneously. Additionally the data suggest that for cytoplasmic
cargo delivery the most important and extensively used endocytosis
route is macropinocytosis, even for the helical CPPs such as TP10.
The involvement of CME and caveolae/lipid-raft mediated endocyto-
sis depends on the CPP concentration (Table 4).
In the time frame of our experiments, the treatment with an endo-
somolytic agent CQ increases the cytoplasmic entry of only the fast
uptake group peptides Tat, TP10 and MAP. In case of pVec, M918
and EB1 the CQ tends to inhibit the overall uptake rather than in-
crease it and the overall uptake of penetratin and TP10(Cys) is not af-
fected by CQ at all. It seems that the endosomolytic effects of CQ arenot revealed that clearly during the short course of our experiment.
This is not surprising as similar effects have also been seen elsewhere
where CQ treatment led to lowered short term CPP uptake while the
long term biological effect was increased nevertheless [47]. CQ treat-
ment reduces the overall endosomal trafﬁcking rate, especially in
early time points because it slows down the endosome acidiﬁcation
and overall endocytic machinery [49]. Many assays actually seem to
beneﬁt from this process as it gives more time for the internalized
conjugates to enter cells before being recycled back to cell membrane.
However, in case of certain peptides CQ induces certain biphasic
change of the uptake rate kinetics proﬁles—uptake rate goes through
a secondary increase later in the experiment (Fig. 2). The effect is pre-
sent at every concentration of the TP10(Cys) and M918 conjugate,
lower concentrations of the MAP and TP10 conjugates, and higher
concentrations of pVec and penetratin.
In case of the slow uptake group peptides the treatments do not
induce any short term toxicity and the cell membrane remains intact.
This suggests that the diffusion of luciferin–CPP conjugates into cells
and the outﬂow of the reducing glutathione from cells is restrained,
thus excluding potential artifacts. Co-treatment with endocytosis in-
hibitors does not change that, except in case of TP10(Cys) and EB1
where CQ tended to slightly compromise the membrane integrity.
High concentrations of the fast uptake group peptides tend to be
toxic after 120 min incubation however it should be pointed out
that the LDH leakage at the 30 min time point is considerably lower
and most of the internalization of these peptides is observed in this
time frame. It seems that the membrane active properties of MAP
and TP10 are increased in the presence of all the used endocytosis in-
hibitors, but again this is restricted to high peptide concentrations
and long incubation times when most of the uptake has already
taken place. Thus the general analysis of the inhibitor-induced
changes in uptake kinetics does not seem to be compromised by the
toxicity. Different toxicity proﬁle may explain to some extent why
the uptake proﬁles of luciferin-TP10 and luciferin-TP10(Cys) conju-
gates are so different. On the other hand, the differences may also
be related to different peptide structures as helical conformation of
TP10 seems to be important for its membrane activity properties
[50,51] and by conjugating luciferin cargo orthogonally to this pep-
tide its helicity proﬁle could be altered.
In conclusion, we have demonstrated that in the cytosolic delivery
of luciferin–CPP conjugates the prevailing uptake route is macropino-
cytosis, even for the fast internalizing group peptides. To a smaller ex-
tent CME and caveolae/lipid-raft dependent endocytosis are involved
too, being in accordance with literature. Furthermore, we have
showed, based on uptake kinetic data analysis, that the involvement
of different endocytosis sub-types may depend on luciferin–CPP con-
centration in case of certain CPPs but not in case of others. These are
extremely important ﬁndings, in our opinion, as they may lead to yet
another CPP-classiﬁcation aspect. Also this exempliﬁes that CPP clas-
siﬁcation and characterization is by far not complete.
510 I. Mäger et al. / Biochimica et Biophysica Acta 1818 (2012) 502–511The involvement of these pathways in the cytosolic luciferin–CPP
delivery is reﬂected when comparing the overall total uptake in se-
lected time points but they are more clearly revealed when analyzing
the kinetic parameters or shapes of the uptake kinetics curves. This
information is valuable for designing new experiments and novel
peptide-based delivery vectors because the incorporated endocytosis
route might deﬁne the fate of the internalized material and its subse-
quent intracellular trafﬁcking.
Supplementary materials related to this article can be found online
at doi:10.1016/j.bbamem.2011.11.020.
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